Abstract
More than a half of plasma proteins are N-glycosylated. Most of them are synthesized, glycosylated, and secreted to the bloodstream by liver and lymphoid tissues. While associations with N-glycosylation are implicated in the rising number of liver, cardiometabolic, and immune diseases, little is known about genetic regulation of this process. Here, we performed the largest genome-wide association study of N-glycosylation of blood plasma proteome in 10,000 individuals. We doubled the number of genetic loci known to be associated with blood N-glycosylation by identifying 16 novel loci and prioritizing 13 novel genes contributing to N-glycosylation. Among these were GCKR, TRIB1, HP, SERPINA1 and CFH genes. These genes are predominantly expressed in the liver and show previously unknown genetic link between plasma protein N-glycosylation, metabolic and liver diseases, and inflammatory response. By integrating glycomics, proteomics, transcriptomics, and genomics, we provide a resource that facilitates deeper exploration of disease pathogenesis and supports discovery of glycan-based biomarkers.
Competing Interest Statement
Y.S.A. is a full-time employee of GSK PLC and receives salary and stock options as compensation. Y.S.A. is a founder and co-owner of PolyKnomics BV, a private organization, providing services, research and development in the field of computational and statistical genomics. G.L. is a founder and owner of Genos Ltd, a biotech company that specializes in glycan analysis and has several patents in the field. O.Z., T.S., F.V. and I.T.-A are employees of Genos Ltd. All other authors declare no conflicts of interest. Other authors declare no competing financial interests.
Funding Statement
The work of S.Sh., A.T., D.M., A.S., Y.S.A. was supported by the Research Program at the Moscow State University (MSU) Institute for Artificial Intelligence. The study was conducted using the UK Biobank resource under application #59345. The work of E.E., Y.A.T was supported by the budget project of the Institute of Cytology and Genetics FWNR-2022-0020. European Communitys Seventh Framework Programme funded project PainOmics (602736). TwinsUK is funded by the Wellcome Trust, Medical Research Council, Versus Arthritis, European Union Horizon 2020, Chronic Disease Research Foundation (CDRF), Zoe Ltd and the National Institute for Health Research (NIHR) Clinical Research Network (CRN) and Biomedical Research Centre based at Guys and St Thomas NHS Foundation Trust in partnership with Kings College London.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
TwinsUK: The TwinsUK Study was approved by London-Westminster Research Ethics Committee (REC reference EC04/015), and Guy's and St Thomas' NHS Foundation Trust Research and Development (R&D). The TwinsUK BioBank was approved by the HRA - Liverpool East Research Ethics Committee (REC reference 19/NW/0187), IRAS ID 258513. All participants provide written, informed consent. EPIC-Potsdam: All participants gave written informed consent for biomedical research, and the study was approved by the Ethics Committee of the State of Brandenburg, Germany. PainOmics: The study was firstly approved by the Institutional Review Boards of IRCCS Foundation San Matteo Hospital Pavia and then by the Institutional Review boards of all clinical centers (King's College London, ZOL Genk/Lanaken, St. Catherine Specialty Hospital) that enrolled patients. Copies of approvals were provided to the European Commission before starting the study. Written informed consent was obtained from all participants. SOCCS: All participants gave written informed consent and study approval was from the MultiCentre Research Ethics Committee for Scotland and Local Research Ethics committee. SABRE: All participants gave written informed consent. Approval for the baseline study was obtained from Ealing, Hounslow, and Spelthorne, Parkside and University College London research ethnics committees. QMDiab: The initial study was approved by the Institutional Review Boards of HMC and Weill Cornell Medicine-Qatar (WCM-Q) (research protocol #11131/11). Written informed consent was obtained from all participants. CEDAR: The experimental protocol was approved by the ethics committee of the University of Liege Academic Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The full genome-wide summary association statistics for the 117 N-glycome traits will be made publicly available upon publication of the paper.
